Saturday 17 October 2026
Export RGEN’s income statement to Excel — free account
Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.
175.20
8.97
−4.87%
Follow RGEN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
89.00 | 50.77 | 138.79 | 205.56 | 168.10 | 113.18 | 48.21 | 267.52 | 0.00 | 188.34 |
Piotroski F-Score |
3 | 5 | 5 | 5 | 6 | 5 | 4 | 4 | 4 | 6 |
P/S ratio |
10.00 | 10.03 | 11.90 | 16.55 | 27.50 | 21.73 | 11.21 | 15.80 | 12.69 | 12.48 |
Altman Z-Score |
6.10 | 6.02 | 9.27 | 8.68 | 16.90 | 15.29 | 10.18 | 7.83 | 6.42 | 7.49 |
P/FCF ratio |
322.68 | 118.11 | 115.48 | 101.49 | 277.58 | 305.20 | 107.29 | 133.33 | 83.67 | 215.98 |
Altman Z″-Score (non-manufacturers) |
4.87 | 6.00 | 5.46 | 6.24 | 6.67 | 5.31 | 5.88 | 5.19 | 4.98 | 5.48 |
Beneish M-Score |
(2.52) | (1.25) | (2.36) | (2.53) | (1.96) | (1.75) | (2.41) | (2.42) | (2.76) | (2.52) |
P/Operating CF |
535.21 | 93.11 | 415.53 | 253.01 | 677.22 | 293.64 | 145.19 | 343.71 | 205.52 | 358.49 |
P/B ratio |
6.20 | 2.40 | 3.75 | 4.22 | 6.59 | 8.33 | 4.70 | 5.08 | 4.08 | 4.38 |
Price to Tangible BV |
13.17 | 11.86 | 15.05 | 11.80 | 16.15 | 26.37 | 12.94 | 17.50 | 14.81 | 15.22 |
EV/Sales |
9.56 | 10.20 | 11.95 | 15.43 | 26.27 | 21.36 | 10.95 | 15.53 | 12.44 | 12.27 |
EV/EBITDA |
46.90 | 58.77 | 50.38 | 64.68 | 89.22 | 65.94 | 31.63 | 82.71 | 157.32 | 60.17 |
EV/Operating CF |
132.87 | 82.56 | 70.74 | 62.06 | 153.67 | 120.35 | 51.00 | 86.19 | 44.98 | 77.15 |
EV/FCF |
308.33 | 120.09 | 115.98 | 94.66 | 265.25 | 300.03 | 104.81 | 131.03 | 81.98 | 212.32 |
Quick Ratio |
7.49 | 7.99 | 1.77 | 12.03 | 2.47 | 1.92 | 1.83 | 5.31 | 7.03 | 6.82 |
Current Ratio |
8.74 | 9.63 | 2.12 | 13.28 | 2.83 | 2.48 | 2.47 | 6.74 | 8.41 | 8.37 |
Net Debt/EBITDA |
(2.18) | (3.04) | (1.96) | (4.66) | (4.15) | (1.13) | (0.75) | (1.45) | (4.62) | (1.50) |
Debt/Assets |
32.98% | 13.35% | 13.36% | 16.91% | 14.18% | 15.15% | 16.42% | 20.47% | 18.57% | 18.38% |
Debt/Equity |
0.56 | 0.17 | 0.17 | 0.22 | 0.18 | 0.20 | 0.22 | 0.30 | 0.27 | 0.26 |
Asset Turnover |
0.48 | 0.27 | 0.26 | 0.25 | 0.22 | 0.31 | 0.33 | 0.24 | 0.22 | 0.26 |
Operating CF/Net income |
0.64 | 0.62 | 1.97 | 3.14 | 1.05 | 0.93 | 0.93 | 3.20 | (6.87) | 2.40 |
Capex/Depreciation |
(0.80) | (0.52) | (0.70) | (0.82) | (0.69) | (1.43) | (2.53) | (0.55) | (0.39) | (0.27) |
Interest Coverage |
4.24 | 2.17 | 3.87 | 3.88 | 6.48 | 14.83 | 193.35 | 19.06 | (1.69) | 2.56 |
| 8.01% | 7.46% | 2.75% | 2.56% | 4.63% | 7.82% | 10.16% | 1.84% | (1.30%) | 2.40% | |
| 5.37% | 5.49% | 2.19% | 1.97% | 3.63% | 6.02% | 7.61% | 1.33% | (0.90%) | 1.69% | |
ROIC |
8.17% | 1.69% | 3.09% | 2.97% | 4.03% | 6.95% | 8.25% | 1.66% | (1.26%) | 1.83% |
Return on Tangible Assets |
6.56% | 11.81% | 9.33% | 3.34% | 9.22% | 18.83% | 23.70% | 3.08% | (2.24%) | 4.12% |
Average Days of Receivables |
55.98 | 71.68 | 67.26 | 58.98 | 71.14 | 63.92 | 52.94 | 71.67 | 77.16 | 78.41 |
Research and Development Expense of Revenue |
7.04% | 6.14% | 8.15% | 7.20% | 5.51% | 5.11% | 5.48% | 6.76% | 6.81% | 7.34% |
Selling, General and Administrative Expense of Revenue |
29.51% | 36.47% | 33.86% | 35.38% | 32.66% | 27.42% | 26.93% | 34.57% | 41.51% | 39.35% |
Intangible Assets out of Total Assets |
0.31 | 0.63 | 0.60 | 0.49 | 0.48 | 0.51 | 0.48 | 0.49 | 0.51 | 0.51 |
Share Based Compensation of Revenue |
4.40% | 4.78% | 5.25% | 4.75% | 4.64% | 4.10% | 3.41% | 4.04% | 7.58% | 4.42% |
Graham Net Nets |
0.06 | 0.06 | 0.05 | 0.07 | 0.05 | 0.02 | 0.04 | 0.02 | 0.03 | 0.03 |
Graham Number |
6.29 | 15.94 | 10.97 | 14.90 | 27.32 | 40.92 | 51.03 | 23.06 | 0.00 | 27.08 |
Earnings Yield |
1.12% | 1.97% | 0.72% | 0.49% | 0.59% | 0.88% | 2.07% | 0.37% | (0.31%) | 0.53% |
Free Cash Flow Yield |
0.31% | 0.85% | 0.87% | 0.99% | 0.36% | 0.33% | 0.93% | 0.75% | 1.20% | 0.46% |
Revenue per Share |
3.11 | 3.69 | 4.43 | 5.59 | 6.97 | 12.19 | 14.45 | 11.35 | 11.34 | 13.13 |
Operating CF per Share |
0.22 | 0.46 | 0.75 | 1.39 | 1.19 | 2.16 | 3.10 | 2.04 | 3.14 | 2.09 |
Capex per Share |
(0.13) | (0.14) | (0.32) | (0.48) | (0.50) | (1.30) | (2.40) | (0.70) | (0.59) | (0.45) |
Free Cash Flow per Share |
0.10 | 0.31 | 0.43 | 0.91 | 0.69 | 0.87 | 0.70 | 1.34 | 2.55 | 1.63 |
Cash per Share |
4.22 | 4.54 | 4.43 | 11.12 | 13.65 | 10.98 | 11.25 | 13.48 | 13.54 | 13.65 |
Shareholders Equity per Share |
5.03 | 15.47 | 14.06 | 21.92 | 29.10 | 31.81 | 34.45 | 35.26 | 35.27 | 37.45 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.03 | 15.47 | 14.06 | 21.92 | 29.10 | 31.81 | 34.45 | 35.26 | 35.27 | 37.45 |
Free Cash Flow |
3.24 | 12.00 | 18.73 | 44.06 | 36.28 | 47.74 | 38.74 | 74.93 | 142.49 | 91.93 |
Working Capital |
163.08 | 217.57 | 145.90 | 593.52 | 583.43 | 556.42 | 593.92 | 946.40 | 939.25 | 1,001.56 |
Capital Expenditures |
(4.28) | (5.45) | (14.04) | (23.15) | (26.34) | (71.28) | (133.35) | (38.99) | (32.90) | (25.49) |
Net Current Asset Value |
64.00 | 90.81 | 116.69 | 301.48 | 528.65 | 323.39 | 377.22 | 245.01 | 209.09 | 293.82 |
EV/EBIT |
62.56 | 102.87 | 89.20 | 115.60 | 137.83 | 85.64 | 39.06 | 205.82 | 0.00 | 164.20 |
Capex to Sales |
0.04 | 0.04 | 0.07 | 0.09 | 0.07 | 0.11 | 0.17 | 0.06 | 0.05 | 0.03 |
Price to Operating Income |
65.47 | 101.17 | 88.82 | 123.93 | 144.24 | 87.12 | 39.99 | 209.42 | 0.00 | 167.03 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.36 | 0.47 | 0.62 | 0.59 | 0.57 | 0.40 | 0.28 | 0.34 | 0.43 | 0.51 |
Cash ROIC |
0.80% | 1.39% | 2.05% | 2.40% | 1.44% | 1.76% | 1.31% | 2.27% | 4.38% | 2.69% |
Accounts Receivable Turnover |
7.63 | 6.45 | 6.11 | 6.81 | 6.37 | 7.10 | 6.86 | 5.26 | 4.91 | 5.04 |
Accounts Payable Turnover |
8.00 | 10.86 | 9.74 | 10.87 | 11.07 | 10.52 | 10.85 | 15.02 | 13.92 | 11.33 |
Inventory Turnover |
2.21 | 2.11 | 2.13 | 2.45 | 2.09 | 2.00 | 1.64 | 1.61 | 2.08 | 2.25 |
Average Days of Payables |
39.21 | 39.64 | 44.24 | 35.01 | 39.34 | 47.31 | 29.08 | 20.18 | 32.60 | 31.12 |
Days of Inventory on Hand |
191.31 | 212.33 | 178.27 | 168.04 | 221.43 | 241.12 | 251.49 | 208.65 | 145.03 | 176.75 |
Average Receivables |
13.71 | 21.89 | 31.75 | 39.71 | 57.53 | 94.40 | 116.83 | 120.20 | 129.14 | 146.35 |
Average Payables |
5.89 | 6.17 | 8.89 | 10.96 | 14.15 | 26.54 | 31.88 | 23.56 | 25.85 | 31.07 |
Average Inventory |
21.35 | 31.85 | 40.63 | 48.55 | 74.93 | 139.76 | 211.39 | 220.30 | 172.64 | 156.71 |
Average Assets |
217.58 | 516.22 | 759.07 | 1,087.37 | 1,651.50 | 2,130.62 | 2,444.98 | 2,681.39 | 2,830.43 | 2,889.68 |
Average Common Equity |
145.76 | 380.16 | 603.56 | 837.67 | 1,294.46 | 1,639.61 | 1,830.38 | 1,937.77 | 1,968.78 | 2,039.42 |
Columns are period end dates